Literature DB >> 32162427

Pain Management for Medical and Surgical Abortion Between 13 and 24 Weeks Gestation: A Systematic Review.

Emily Jackson1, Nathalie Kapp1.   

Abstract

BACKGROUND: High-quality abortion care requires pain be effectively managed, however practices differ, and available guidelines do not specify optimal strategies.
OBJECTIVES: To guide providers in effective pain management for second-trimester medical and surgical abortion. SEARCH STRATEGY: We searched Pubmed, Cochrane, Embase databases and the US National Library of Medicine clinical trials registry through June 2019 and hand-searched reference lists. SELECTION CRITERIA: Trials comparing pain management strategies to no treatment, placebo, or active interventions during induced medical or surgical abortion between 13 and 24 gestational weeks and reporting direct or indirect measures of pain. DATA COLLECTION AND ANALYSIS: Both authors summarized and systematically assessed evidence and risk of bias using standard tools. MAIN
RESULTS: We included seven medical and four surgical abortion studies, with 453 and 349 participants, respectively. Heterogeneity of interventions and outcomes prevented pooled analyses. Medical abortion: women receiving routine or continuous epidural analgesia experienced mild pain. Prophylactic NSAIDs decreased pain (mean difference -0.5, p<0.001) and additional opioid requirements (3.5mg vs 7mg, p=0.04) compared to placebo/other treatment. Paracervical block was ineffective. No studies assessed IM/IV opioids or nonpharmacologic treatment. Surgical abortion: general anesthesia/deep IV sedation alleviated pain. Nitrous oxide was ineffective. No studies assessed moderate IV sedation, IV/IM opioids, paracervical block without sedation, NSAIDs or nonpharmacologic treatment.
CONCLUSIONS: Based on limited data, regional analgesia and NSAIDs mitigated second-trimester medical abortion pain; general anesthesia/deep IV sedation alleviated surgical abortion pain. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  dilatation and evacuation; induced abortion; medical abortion; pain management; second trimester

Year:  2020        PMID: 32162427     DOI: 10.1111/1471-0528.16212

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  6 in total

1.  Maternal non-steroidal anti-inflammatory drug exposure during pregnancy and risk of miscarriage: a systematic review and meta-analysis.

Authors:  Xian-Hua Ying; Dan-Ni Bao; Hai-Yin Jiang; Yu-Dan Shi
Journal:  Eur J Clin Pharmacol       Date:  2021-10-11       Impact factor: 2.953

2.  Pain, Side Effects, and Abortion Experience Among People Seeking Abortion Care in the Second Trimester.

Authors:  Ilana G Dzuba; Sruthi Chandrasekaran; Laura Fix; Kelly Blanchard; Erin King
Journal:  Womens Health Rep (New Rochelle)       Date:  2022-05-12

3.  Exploring interactions between women who have experienced pregnancy loss and obstetric nursing staff: a descriptive qualitative study in China.

Authors:  Jialu Qian; Weihong Wang; Shiwen Sun; Mengwei Wu; Lu Liu; Yaping Sun; Xiaoyan Yu
Journal:  BMC Pregnancy Childbirth       Date:  2022-05-30       Impact factor: 3.105

4.  Intrathecal Fentanyl With a Paracervical Block Is Safe and Effective for Elective Termination of Pregnancy in a Patient With Primary Pulmonary Hypertension.

Authors:  Joshua Younger; Mohamed Fayed; Gaurav Chauhan; Nicholas Mantel; Donald Penning
Journal:  Cureus       Date:  2022-02-28

5.  Dispensing of Potentially Harmful Prescription Drugs in 1.8 Million Pregnant Women in France: A Nationwide Study Based on Two Risk Classification Systems.

Authors:  Pierre-Olivier Blotière; Christine Damase-Michel; Alain Weill; Géric Maura
Journal:  Drug Saf       Date:  2021-10-06       Impact factor: 5.606

6.  Evaluation efficacy and safety of epidural analgesia in second-trimester induced labor: A single-center, prospective, non-randomized, controlled study.

Authors:  Yong Zeng; Tao Jiang; Ya-Hong Zheng; Wen-Rong He; Xiao-Wen Wang; Hua Wei; Li Wang; Zu-Rong Liu; Xu-Feng Zhang; Cunjian Yi; Ke-Ming Chen
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.